Aventis Pharmaceuticals Inc.

Sanofi

Jeffrey Stephen Sabol

Gregory H Merriman

Alexandre Gross

Liang Ma

Daniel Gerard McGarry

Sukanthini Thurairatnam

John Ziqi Jiang

David Rampe

Patrick Shum

Francis A Volz

Garth E Ringheim

Christopher Loren Vandeusen

Lan Mu

Suzanne C Aldous

Nicholas J Hrib

John G Jurcak

Barbara S Rauckman

Philip M Weintraub

Brian K Whiteley

Ramalinga M Dharanipragada

Brian L Pedgrift

Kwon Yon Musick

Joseph T Klein

Stanly John

Jinqi Lu

Harry Randall Munson

Christopher L Vandeusen

Michael W Fennie

James R Pribish

Grzegorz T Stoklosa

Stephen Ayers

Yang Cao

Daniel G Mcgarry

Alexandre 245 Eighth Street Gross

This invention is directed to a compound of formula (I): wherein R, R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine hydrazide compounds as PGDS inhibitors

This invention is directed to a compound of formula (I): wherein R, R, Rand Lare as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

Pyrimidine amide compounds as PGDS inhibitors

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R, R, R, R, R, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.

Heterocyclic compounds as P2X7 ion channel blockers

This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.

Indole derivatives as interleukin-4 gene expression inhibitors

Methods of determining the potency, specificity, and toxicity of microsomal prostaglandin E2 synthase inhibitors are provided that utilize one cell-based assay system.

Methods for determining the potency, specificity, and toxicity of microsomal prostaglandin E2 synthase

Growing community of inventors

Bridgewater, NJ, United States of America

Jeffrey Stephen Sabol